Braftovi 75mg

Braftovi 75 mg contains encorafenib, a targeted anticancer medicine that belongs to a class of drugs known as BRAF inhibitors. It works by blocking the activity of certain abnormal BRAF proteins involved in cancer cell growth and division.

The BRAF gene provides instructions for producing a protein that helps regulate cell growth. Certain mutations, particularly the BRAF V600E mutation, can cause this protein to remain abnormally active, encouraging cancer cells to grow and multiply. Encorafenib helps inhibit this signaling pathway and may slow the progression of cancers with specific BRAF mutations.

Braftovi is used in combination with other medicines for certain types of cancer, including BRAF-mutated melanoma and metastatic colorectal cancer. Depending on the indication, it may be prescribed with binimetinib or cetuximab. Its use depends on the cancer type, confirmed mutation status, previous treatments, and the patient’s overall health. Treatment must be prescribed and monitored by an oncologist.

How Does Braftovi 75 mg Capsule Work?

Braftovi 75 mg is an oral targeted therapy that contains encorafenib. It works by inhibiting the activity of abnormal BRAF proteins that contribute to cancer cell growth and multiplication.

The BRAF protein is part of the MAPK signaling pathway, which regulates cell growth and survival. Certain mutations can overactivated this pathway, allowing cancer cells to grow uncontrollably. Encorafenib blocks the activity of mutated BRAF proteins, helping interrupt these signals and slow cancer progression.

Braftovi is commonly used with binimetinib for eligible patients with unresectable or metastatic melanoma and certain cases of metastatic non-small cell lung cancer. It may also be combined with cetuximab, with or without fluorouracil-based chemotherapy, for BRAF V600E-mutated metastatic colorectal cancer.

Treatment response varies depending on the cancer type, mutation status, combination medicines, and individual health factors. Braftovi requires specialist supervision because it can cause serious adverse reactions.

Dosage of Braftovi 75 mg Capsules :

Braftovi 75 mg contains encorafenib and is available as an oral capsule. It is prescribed in combination with other medicines for specific cancers with confirmed BRAF mutations. The dosage must be determined by an oncologist according to the approved treatment regimen.

The FDA-recommended dosage for eligible patients varies by cancer type:

• Melanoma: 450 mg (six 75 mg capsules) once daily with binimetinib.
• Metastatic non-small cell lung cancer: 450 mg (six 75 mg capsules) once daily with binimetinib.
• Metastatic colorectal cancer: 300 mg (four 75 mg capsules) once daily with cetuximab and an appropriate chemotherapy regimen, or with cetuximab alone after prior therapy, as indicated.

Braftovi may be taken with or without food. The prescribed dosage may be adjusted or treatment interrupted if adverse reactions occur or other medicines affect encorafenib levels.

Patients should follow their oncologist’s instructions, avoid doubling a missed dose, and consult their healthcare professional before making any changes to treatment.

Benefits of Using Braftovi 75 mg Capsules :

Braftovi 75 mg is a targeted anticancer medicine that helps inhibit abnormal BRAF signaling in cancers with specific genetic mutations. Its potential benefits depend on the diagnosis, treatment combination, and individual response.

• Targeted treatment: Encorafenib blocks abnormal BRAF protein activity involved in cancer cell growth.
• Melanoma treatment: When combined with binimetinib, it is used for eligible patients with unresectable or metastatic melanoma carrying BRAF V600E or V600K mutations.
• Colorectal cancer treatment: It is used in approved combination regimens for metastatic colorectal cancer with a confirmed BRAF V600E mutation.
• Lung cancer treatment: In combination with binimetinib, it is indicated for eligible adults with metastatic non-small cell lung cancer carrying a BRAF V600E mutation.
• Oral administration: Capsules provide a convenient oral route of administration when prescribed and monitored by a specialist.
• Treatment planning: Mutation testing helps identify patients who may benefit from this targeted therapy.

Braftovi may help control cancer progression in eligible patients, but it does not guarantee a cure. Treatment effectiveness and tolerability vary from person to person.

Side Effects of Braftovi 75 mg Capsules :

Braftovi may cause mild to serious side effects. Their frequency and severity can vary depending on the patient’s health, dosage, and other medicines used in combination therapy.

Commonly reported side effects include:

• Fatigue and weakness
• Nausea and vomiting
• Diarrhea and abdominal pain
• Decreased appetite
• Skin rash and other skin changes
• Joint pain
• Constipation
• Peripheral neuropathy, including tingling or numbness, particularly with certain colorectal cancer regimens

Serious risks include bleeding, liver problems, heart muscle dysfunction, QT interval prolongation, eye inflammation, and the development of new skin or other cancers. Braftovi can also cause harm to an unborn baby.

Seek prompt medical attention for severe or unusual bleeding, chest pain, fainting, significant vision changes, yellowing of the skin or eyes, or other concerning symptoms.

Regular medical assessments and laboratory tests are important during treatment. Patients should inform their healthcare team about all medications and supplements they take to help prevent potentially harmful drug interactions.

Conclusion :

Braftovi 75 mg (encorafenib) is a prescription targeted therapy used in combination with other medicines for certain BRAF-mutated cancers, including melanoma, colorectal cancer, and non-small cell lung cancer. Its suitability, dosage, and treatment duration depend on mutation testing, the cancer type, and individual health factors. Specialist supervision and regular monitoring are essential throughout treatment.

Important Medical Warning :

Use Braftovi 75 mg only under the direction of a qualified oncologist. Follow the prescribed dosage, administration instructions, and monitoring schedule. Do not start, stop, or change the dose without consulting your healthcare professional. Inform your doctor about other medications, existing health conditions, and pregnancy or breastfeeding considerations before starting treatment.